ライフサイエンスコーパス: inotrope

1 ulatory support, or hospital discharge on an inotrope.

2 as been shown ex vivo to be a potent cardiac inotrope.

3 /- 63.1 vs. 215.5 +/- 68.1), and duration of inotrope.

4 cardia and intractable hypotension requiring inotropes.

5 d lower cumulative doses of vasopressors and inotropes.

6 or to that of patients who were bridged with inotropes.

7 rbidity scores, and need for vasopressors or inotropes.

8 xic antimicrobials, vasopressin, or specific inotropes.

9 ssure, peripheral edema, ascites, and use of inotropes.

10 cts that are commonly observed with positive inotropes.

11 anted, 32 received LVADs, and 50 remained on inotropes.

12 evaluates contemporary outcomes on long-term inotropes.

13 in patients who were offered LVAD but chose inotropes (15 patients), and for palliation (98 patients

14 Listings with low-dose inotropes (-18%) and high-dose inotropes (-3%) significa

15 dy, 68 patients had died, 24 were weaned off inotropes, 23 were transplanted, 32 received LVADs, and

16 with low-dose inotropes (-18%) and high-dose inotropes (-3%) significantly decreased.

17 ortic balloon pump usage (8.5% versus 7.5%), inotrope (39% versus 50%) and vasoconstrictor usage (66%

18 % versus 5.3%; P<0.001), require intravenous inotropes (41.4% versus 37.2%; P<0.001), and were less l

19 male patients), patients were on 2.0 +/- 0.9 inotropes, 7 (35) had an intra-aortic balloon pump, 2 we

20 tilation, 8% versus 19%; vasopressors and/or inotropes, 9% versus 16%; vasodilators, 6% versus 12%; a

21 then manipulated by fluid administration or inotrope adjustment, and the readings were repeated.

22 therapy, a higher percentage were prescribed inotropes after publication (3272 [21.5%] of 15 193 pati

23 Although the use of inotropes also decreased during the period under study,

24 We conclude that beta-MyHC is a negative inotrope among the cardiac myofilament proteins.

25 reatment choice, or fluid, vasopressors, and inotrope amounts.

26 Combination therapy with a positive inotrope and a beta-blocker appears to be useful in the

27 s ratio: 1.5; p < 0.0001) compared with dual-inotrope and intra-aortic balloon pump support.

28 Score II, even when assessing the effect of inotrope and vasoactive treatments at 24, 48, and 72 hou

29 r and peak cTnT, ECG changes, cardiac index, inotrope and vasoconstrictor use, renal dysfunction, and

30 udes the management of neuraxial anesthesia, inotrope and vasopressor support, transthoracic echocard

31 esulted in the identification of 17 positive inotropes and 21 positive lusitropes, almost all of them

32 the DCDD group, donor age < 40 years, use of inotropes and absence of gag/cough reflexes were predict

33 or poor ejection fraction, and the need for inotropes and an intra-aortic balloon pump (OR 1.72 to 4

34 etween mortality and compliance with each of inotropes and red cell transfusions, glucocorticoids, an

35 Status 1A registrants supported with dual inotropes and right heart monitoring had a higher risk o

36 hat cooling can reduce the need for positive inotropes and that lower rather than higher temperatures

37 Twenty-one patients required intravenous inotropes and three patients required extracorporeal mem

38 probability of inadequate oxygen delivery on inotropes and vasoactive infusions (IVAI) postoperativel

39 ) over 5 to 10 mins (2C); more common use of inotropes and vasodilators for low cardiac output septic

40 es the use of vasoactive medications such as inotropes and vasodilators.

41 eart rate of >120 beats/min, requirement for inotropes and vasopressors after surgery and on admissio

42 Inotropes and vasopressors are widely used to improve he

43 n 80/85 and 100 mm Hg with additional use of inotropes and vasopressors was associated with smaller m

44 All inotropes and vasopressors were discontinued within 12 h

45 Inotropes and vasopressors were not administered to eith

46 Inotropes and vasopressors worsened left-to-right shunti

47 et of symptoms <1 month) of whom 55 required inotropes and/or mechanical circulatory support (FM) and

48 uscitated using crystalloids, supported with inotrope, and antibiotics.

49 th longer ischemic times, longer duration of inotrope, and correspond with higher glucose levels.

50 replacement therapy, use of vasopressors and inotropes, and association with cardiac index, lactate,

51 Goal-directed therapy using fluids, inotropes, and blood transfusion reduced 30-day major co

52 , in which intravenous fluids, vasopressors, inotropes, and blood transfusions were adjusted to reach

53 the use of intravenous fluids, vasopressors, inotropes, and blood transfusions.

54 iod; administration of fluids, vasopressors, inotropes, and packed red blood cells titrated to hemody

55 rgery, mechanical ventilation, vasopressors, inotropes, and pulmonary vasodilators.

56 than 3 L/min/m was targeted with IV fluids, inotropes, and RBC transfusion starting from cardiopulmo

57 ristics, hemodynamic and clinical changes on inotropes, and survival were evaluated.

58 ndothelium-dependent vasodilators and potent inotropes, and the apelin system has a reciprocal relati

59 Crystalloids, colloids, blood, inotropes, and vasopressors were used by predetermined a

60 itted to ICU in frank septic shock requiring inotropes, and with demonstrable septic myocardial depre

61 risk (P=0.012 and P=0.006 compared with non-inotrope- and inotrope-based controls, respectively), as

62 0.003) or any control therapy, including non-inotrope- and inotrope-based therapies (RR(MH), 1.54; 95

63 Inotropes are effective as a bridge to transplant/LVAD.

64 hat increase cardiac contractility (positive inotropes) are theoretically appealing as a heart failur

65 lume index of <30 mL/min/m2, requirement for inotropes, arterial bicarbonate of <20 mmol/L, plasma gl

66 ion fraction <30%, pre-operative intravenous inotropes, arterial vascular disease, and higher degree

67 Of 60 patients who were placed on inotropes as a bridge to transplant/LVAD, 55 were succes

68 effects and to determine in vivo efficacy of inotropes as anti-inflammatory agents.

69 Based on these data, the routine use of inotropes as heart failure therapy is not indicated in e

70 LOF was defined as the need for >/=2 inotropes at 48 hours, an intra- or post-operative intra

71 (OR, 1.5; 95% CI, 1.1-2.0), support with >/=inotropes at HT (OR, 1.7; 95% CI, 1.2-2.5), hospitalizat

72 f worsening renal function compared with non-inotrope-based control (RR(MH), 1.52; 95% CI, 1.16 to 2.

73 and P=0.006 compared with non-inotrope- and inotrope-based controls, respectively), as did nesiritid

74 control therapy, including non-inotrope- and inotrope-based therapies (RR(MH), 1.54; 95% CI, 1.19 to

75 scular problems from overuse of diuretics or inotropes because of the unusual loading conditions in T

76 Positive inotropes, beta1-AR agonists, are used to improve cardia

77 tinotrope data on 197 patients discharged on inotropes between January 2007 and March 2013.

78 ist device support within 30 days, or use of inotropes beyond 14 days.

79 but include medical therapy with intravenous inotropes, biventricular assist devices (Bi-VADs) and th

80 Dobutamine was superior to dopamine as an RV inotrope, both ex vivo and in vivo.

81 The degree to which positive inotropes can improve patient-reported health status and

82 Concurrently, the status 1A inotrope candidate waitlist outcomes improved substantia

83 waitlist death or deterioration of status 1A inotrope candidates relative to status 2 candidates decr

84 to determine whether candidates listed with inotropes contribute to the excess status 1A candidates.

85 nds suggest that overtreatment with multiple inotropes contributes to the current critical excess of

86 levant concentrations of stress hormones and inotropes could directly affect the iron binding of seru

87 We report that 17 positive and 9 negative inotropes covering diverse mechanisms of action exerted

88 In contrast to existing pharmacological inotropes, CRT both acutely and chronically increases ca

89 all cause mortality, retransplantation, and inotrope dependence.

90 n of Nontransplant-Eligible Patients Who Are Inotrope Dependent) trial was a prospective, nonrandomiz

91 ntubated and on prostaglandin, 24 (89%) were inotrope dependent, and 22 (81%) had no antegrade flow f

92 s, and 78% (range, 68%-86%) of patients were inotrope dependent.

93 ransplant-ineligible ESHF, most of whom were inotrope dependent.

94 most transplant-ineligible patients who are inotrope dependent.

95 Survival was best in patients who were not inotrope-dependent (INTERMACS profiles 4 to 7).

96 In non-inotrope-dependent advanced heart failure patients recei

97 sults was performed to estimate survival for inotrope-dependent and inotrope-independent patients.

98 -year-old man with progressive, debilitating inotrope-dependent heart failure due to ischemic cardiom

99 ) support on survival and quality of life in inotrope-dependent heart failure patients ineligible for

100 Inotrope-dependent heart failure patients who are inelig

101 Confidence that the inotrope-dependent ICER is high value increased to 75% a

102 The inotrope-dependent ICER was sensitive to model input cha

103 eligible patients, mean life expectancy with inotrope-dependent medical therapy is estimated at 9.4 m

104 options for end-stage heart failure include inotrope-dependent medical therapy, orthotopic heart tra

105 ality-adjusted life-year gained, relative to inotrope-dependent medical therapy.

106 ality-adjusted life-year gained, relative to inotrope-dependent medical therapy.

107 </= 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or lis

108 SGD 106 458 (US $79 446) per QALY gained for inotrope-dependent patients and SGD 174 798 (US $130 446

109 , United Network for Organ Sharing status I (inotrope-dependent) heart transplant (n = 3) or urgent i

110 Neutrophil pretreatment with inotropes did not prevent CD11b upregulation.

111 , antibacterials, narcotics, antipsychotics, inotropes, digoxin, anesthetic agents, bronchodilators,

112 Inotropes directly modulate the cardiac nerve plexus to

113 therapy algorithm for intravenous fluid and inotrope (dopexamine) infusion during and 6 hours follow

114 Increase in inotrope dose significantly increased spinal cord perfus

115 MACS-defined RHF was superior to postimplant inotrope duration alone in the prediction of all-cause m

116 d for either mechanical support or high-dose inotrope (epinephrine > or = 0.07 microg/kg/min).

117 al differences; broadly, ssTnI is a positive inotrope, especially under acidic/hypoxic conditions, wh

118 t of patient-centered outcomes in studies of inotropes for end-stage HF with reduced ejection fractio

119 the need for RV assist device or intravenous inotropes for greater than 14 days.

120 Patients who received inotropes for palliation or those who preferred inotrope

121 Survival on inotropes for patients who are not candidates for transp

122 13 [0-25] vs 15 [0-25]; p = 0.8) and pressor/inotrope-free days (median and interquartile range, 25 [

123 eaths) and 65 +/- 10% at three years for the inotrope group (nine deaths; p = 0.007).

124 D group and 44 +/- 9% at three years for the inotrope group (p = 0.01).

125 hs for the LVAD group and 64 +/- 11% for the inotrope group (p = NS).

126 Patients initiated on inotropes had refractory heart failure, with median base

127 Catecholaminergic inotropes have a place in the management of low output s

128 Inotropes have been fundamental to resuscitation of acut

129 Although positive inotropes have failed to show survival benefit, these ag

130 nistration of IVF (low to high certainty) or inotropes (high certainty).

131 rdiogenic shock consists of vasopressors and inotropes; however, these agents can increase myocardial

132 7; P=0.003), defect size (HR=1.09; P=0.026), inotropes (HR=4.18; P=0.005), and absence of revasculari

133 troglycerin, nitroprusside), and intravenous inotropes (ie, dobutamine, milrinone).

134 dio-protective effects and act as a positive inotrope in the cardiovascular system.

135 Endothelin-1 (ET-1) is a potent positive inotrope in vitro, but its physiological effects on intr

136 resent a superior alternative to traditional inotropes in heart failure management.

137 cubation of S epidermidis with catecholamine inotropes in the presence of human plasma resulted in a

138 goal-directed therapy with vasopressors and inotropes in the treatment of sepsis syndrome.

139 subsets of both positive as well as negative inotropes, in a mechanism-related mode.

140 eceiving multiple catecholamine pressors and inotropes, including dobutamine (n=10), epinephrine (n=8

141 Positive inotropes, including phosphodiesterase inhibitors, are a

142 umber of candidates listed as status 1A with inotropes increased by 193 a year, whereas the dobutamin

143 nges and structural assumptions, whereas the inotrope-independent ICER consistently exceeded the high

144 GD 174 798 (US $130 446) per QALY gained for inotrope-independent patients (with 59% and 19% probabil

145 extreme changes rendered LVAD high value for inotrope-independent patients.

146 were required for LVAD to be high value for inotrope-independent patients.

147 estimate survival for inotrope-dependent and inotrope-independent patients.

148 cal generalized linear models (0.113 for any inotrope) indicated that a noteworthy proportion of the

149 ons in operating room hemodynamic practices (inotrope infusion >60 minutes and vasopressor infusion >

150 an- and hospital-level variation existed for inotrope infusion (ICC, 6.2% [95% CI, 4.2%-8.0%] vs 17.9

151 higher for patients at hospitals with higher inotrope infusion rates (adjusted odds ratio [AOR], 1.98

152 mediated cardiac contractile dysfunction and inotrope insensitivity.

153 rapy, bridging to heart transplantation with inotropes is thought to be the preferred treatment optio

154 on in advanced heart failure patients not on inotropes is unclear.

155 The term "inotrope" is familiar and intimately connected with phar

156 In contrast to available inotropes, istaroxime increased SBP and decreased HR.

157 Inotropes may be a necessary evil in a subset of acute h

158 ren were supported with multiple intravenous inotropes+/-mechanical ventilation (6) or ECMO (3) befor

159 spitalization for heart failure, intravenous inotropes, mechanical support, or death.

160 dverse clinical outcomes, including need for inotropes, mechanical ventilation, meningitis, and death

161 dged to heart transplantation with either IV inotropes (n = 38) or an implantable LVAD (n = 66; Heart

162 were not taking beta-blockers or intravenous inotropes (n=470) were followed for 1.5 years.

163 mortality or HF hospitalization were need of inotropes, New York Heart Association class or natriuret

164 val 1.04 to 1.17; p = .005), and infusion of inotropes (odds ratio 4.7; 95% confidence interval 1.3 t

165 Inotropes of interest included adrenergic agents, phosph

166 =6.5 [CI, 1.39-50.15]), and increased use of inotropes on ECMO (OR=3.77 [CI, 1.39-11.07]), whereas LV

167 brane oxygenation cardiac arrest, the use of inotropes on extracorporeal membrane oxygenation, and po

168 Seven patients (22%) required inotropes on leaving the operating room, and 3 patients

169 tratified by bridging modality: no bridging, inotropes only, intra-aortic balloon pump (IABP), tempor

170 ardiovascular effects of a novel intravenous inotrope, OPC-18790, the observed benefits on contractil

171 c readout allowed for the differentiation of inotropes operating via distinct mechanisms.

172 age, greater FiO2 and PEEP requirements and inotrope or anticoagulant use were associated with incre

173 asia, bacterial sepsis, or administration of inotrope or vasopressor).

174 transplantation with either intravenous (IV) inotropes or an implantable left ventricular assist devi

175 t failure needing intravenous treatment with inotropes or diuretics was the most common adverse event

176 stry form; and/or (ii) pre-procedural use of inotropes or mechanical circulatory support devices and/

177 differences in the administration of either inotropes or RBC transfusions.

178 Under these circumstances, treatment with inotropes or renal vasodilators may be more appropriate

179 A total of 55 patients were receiving inotropes or vasodilators.

180 greater risk of patient-important bleeding: inotropes or vasopressors (HR, 2.05 [95% CI = 1.35, 3.12

181 There was a lower need for inotropes or vasopressors with CS (62.8%) versus GA (97.

182 emoglobin >8 g/dL, and no use of intravenous inotropes or vasopressors.

183 stability unresponsive to the usual doses of inotropes or vasopressors.

184 5%, cardiac index </= 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical

185 a central venous catheter, administration of inotropes, or blood transfusions; or usual care.

186 , or any intravenous therapy with diuretics, inotropes, or other vasoactive agents.

187 ATPase-inhibitor, or the calcium-sensitizing inotrope ORG 30029.

188 tropes for palliation or those who preferred inotropes over LVAD had median survival of 9.0 months (i

189 p required more fluid boluses (p < 0.05) and inotropes (p < 0.001).

190 acidosis (P:=0.03), need for bicarbonate or inotropes (P:=0.008 and 0.04), and ventricular dysfuncti

191 PaO2/FIO2 less than 300, use of vasopressors/inotropes, pancreatitis, hepatic failure/cirrhosis with

192 Need of inotropes, persistently high New York Heart Association

193 creatinine concentration >3.0 mg/dL, use of inotropes, presence of myocardial stun, and requirement

194 led Doppler-derived risk groups, intravenous inotrope requirement and blood urea nitrogen as signific

195 ICU admission and predicts ICU mortality and inotrope requirement as well as or better than APACHE II

196 ACR 2 predicted mortality and ACR 1 inotrope requirement independent of clinical mortality r

197 of shock, intensive care unit admission and inotrope requirement, and increased inflammatory markers

198 was associated with reductions in procedural inotrope requirement, intensive care unit and hospital l

199 adjusting for age, sex, listing status, and inotrope requirement, waitlist mortality risk was lower

200 enal dysfunction (44% > 44% > 35% > 29%) and inotrope requirements (52% > 25% > 36% > 29%) were lower

201 unit stay (p = 0.175), survival (p = 0.877), inotrope requirements (p = 0.495), need for extracorpore

202 patients with the TAH have no postoperative inotrope requirements, arrhythmias or inflow/outflow can

203 nical ventilation and biochemical variables, inotrope requirements, extracorporeal membrane oxygenati

204 terio-venous O2 difference (DeltaA-VO2), and inotrope requirements.

205 tive transthoracic echocardiography and peak inotrope requirements.

206 In maladaptive RVH there is reduced inotrope responsiveness because of G-protein receptor ki

207 in both rat and human myocytes, but restored inotrope responsiveness.

208 erapy (odds ratio, 4.89; 3.83-6.28), and for inotrope(s) and/or vasopressor(s) (odds ratio, 3.64; 2.8

209 cluding renal replacement therapy and/or for inotrope(s) and/or vasopressor(s).

210 al replacement therapy was needed in 23% and inotropes(s) and/or vasopressor(s) in 77% of studied pat

211 vity assay of serum troponin T at 72 hours), inotrope score (calculated from the maximum dose of the

212 FIO2, oxygenation index, and 24-hour maximal inotrope score (p</=0.02), although end-tidal alveolar d

213 s 27%), more severe haemodynamic impairment (inotrope score 279 mug/kg per min vs 145 mug/kg per min,

214 ee patients (75%) had a change in Vasoactive-Inotrope Score after the fluid bolus, of whom 60% receiv

215 Organ Dysfunction 2 score, day 0 vasopressor-inotrope score and fluid balance, and PaO2/FIO2 6 hours

216 mplantation, as assessed by their Vasoactive-Inotrope Score and number of organ failures.

217 or less) and severe haemodynamic compromise (inotrope score at least 75 mug/kg per min or lactic acid

218 aO2/FIO2, oxygenation index, 24-hour maximal inotrope score, and Pediatric Risk of Mortality III (all

219 nation of oxygenation index, 24-hour maximal inotrope score, and Pediatric Risk of Mortality III.

220 nation of oxygenation index, 24-hour maximal inotrope score, and Pediatric Risk of Mortality III.

221 Hemodynamics, inotrope score, and serum sodium did not differ between

222 ore-1, Pediatric Logistic Organ Dysfunction, inotrope score, duration of ventilation and pediatric IC

223 l length of stay, primary graft dysfunction, inotrope score, mechanical circulatory support use, cere

224 t ventricular (RV) adrenergic remodeling for inotrope selection and the therapeutic benefit of interr

225 100 versus 107 mm Hg in those not receiving inotropes, serum sodium was 134 versus 137 mEq/L, and le

226 d Circulatory Support class, use of multiple inotropes, severe right ventricular dysfunction on echoc

227 a possible mechanism by which catecholamine inotropes stimulate bacterial growth as biofilms.

228 n in both adrenergic receptor expression and inotrope-stimulated cAMP levels (P<0.01).

229 While inotropes successfully increase cardiac output, their us

230 d that clinically relevant concentrations of inotropes, such as amrinone and dopamine, which increase

231 Currently available inotropes, such as dobutamine and milrinone, act (direct

232 .25]; RD, -0.09 [95% CI, -0.22 to 0.05]), or inotrope support (RR, 0.77 [95% CI, 0.51 to 1.17]; RD, -

233 d as the need for post-operative intravenous inotrope support for >14 days, inhaled nitric oxide for

234 rt, mechanical ventilation with vasopressors/inotrope support, mechanical ventilation without hemodyn

235 (95% confidence interval: 4% to 8%) for dual inotrope support.

236 are, including 7 patients (25%) who required inotrope support.

237 This underscores an unmet need for positive inotropes that improve heart function without any advers

238 neutrophils were pretreated with or without inotropes, then stimulated with n-formyl methyl leucine

239 exception requests and fewer candidates with inotrope therapy than expected, thus leading to signific

240 90 mm Hg, and red blood cell transfusions or inotropes to attain a central venous oxygen saturation o

241 ive iron showed the ability of catecholamine inotropes to facilitate acquisition of iron by S epiderm

242 s in 2006, transplant programs used multiple inotropes to list candidates at status 1A more frequentl

243 ability of catecholamine stress hormones and inotropes to stimulate the growth of infectious bacteria

244 Myocardial failure, leading to inotrope-unresponsive shock, is the predominant cause of

245 ant/LVAD, 55 were successfully maintained on inotropes until transplant/LVAD.

246 pass, 2.6%; intraaortic balloon pumps, 1.0%; inotrope usage, 0.8%; combination, 1.0%).

247 curring in the setting of hypovolemia and/or inotrope usage.

248 trograde cardioplegia had significantly less inotrope use (71% versus 84%, P:=0.002), right ventricul

249 ), a medical diagnosis (hazard ratio, 1.43), inotrope use (hazard ratio, 3.47), and treatment limitat

250 % CI, 1.2-8.2), and had a longer duration of inotrope use (median, 5.5 [IQR, 4-8] vs 4.0 [IQR, 3-6] d

251 1 to 5.70; P<0.001), intraoperative multiple inotrope use (OR, 2.75; CI, 1.75 to 4.31; P<0.001), intr

252 Inotrope use (score) was higher in the PGD group at 24,

253 47; P=0.0001) and a significant reduction in inotrope use 6 to 12 hours postoperatively (odds ratio,

254 t to characterize institutional variation in inotrope use among patients hospitalized with heart fail

255 sociation between risk-standardized rates of inotrope use and clinical outcomes was determined.

256 te hospital-level risk-standardized rates of inotrope use and risk-standardized in-hospital mortality

257 y of atrial fibrillation, those who required inotrope use during or after surgery, and those having v

258 , including mean arterial blood pressure and inotrope use during the 48 h after hypoxia-ischaemia.

259 Hospitals with higher risk-standardized inotrope use had modestly longer risk-standardized lengt

260 Inotrope use in heart failure treatment was associated w

261 The risk-standardized rates of inotrope use ranged across hospitals from 0.9% to 44.6%

262 icated that 21% of the observed variation in inotrope use was potentially attributable to random hosp

263 Patterns of inotrope use were stable during the 7-year study period.

264 ed risk-standardized hospital-level rates of inotrope use within 209 hospitals participating in Get W

265 trolling for severity of oxygenation defect, inotrope use, and severity of illness.

266 The VVR score incorporates measures of inotrope use, ventilation support, and kidney function t

267 lmonary bypass, anesthesia, ventilation, and inotrope use; and complication and reintervention rates.

268 l ventilation, intensive care unit stay, and inotrope use; and fewer electrolyte abnormalities.

269 CS was defined as the coding of: 1) CS; 2) inotrope use; or 3) mechanical circulatory support befor

270 ical ventilation, or higher vasopressors and inotropes use.

271 The ICER differed for inotrope-use subgroups at SGD 106 458 (US $79 446) per Q

272 Use of inotropes varied significantly between hospitals even af

273 ies (n = 149, 51.0%) including chemotherapy, inotropes, vasoactive agents, and sedatives were the mos

274 Inotropes, vasodilators (children), inhaled nitric oxide

275 ial diuretic requirement despite intravenous inotropes/vasodilators.

276 ho have metabolic acidosis, a bicarbonate or inotrope/vasopressor requirement, cardiopulmonary resusc

277 emography, clinical classification, outcome, inotrope/vasopressor requirement, clinical assessment of

278 ion (33%), mechanical ventilation (26%), and inotrope/vasopressor therapy (26%) were common.

279 ascular dysfunction (47% versus 23% received inotrope/vasopressor therapy; P = 0.02).

280 cal treatment for cardiogenic shock includes inotropes, vasopressors and diuretics.

281 ients with cardiogenic shock unresponsive to inotropes/vasopressors and intraaortic balloon pumps (IA

282 ation II Score of 22.0 (7.8); 61.2% received inotropes/vasopressors on study day 1.

283 or illness severity, mechanical ventilation, inotropes/vasopressors, renal replacement therapy, and s

284 eased significantly, and the requirement for inotropes was reduced significantly.

285 tients who were not status 1A or required >1 inotrope were excluded.

286 Inotropes were not altered, and no transfusions were giv

287 Inotropes were prescribed based on transesophageal echoc

288 In this study, six known inotropes were profiled using the work-loop technique to

289 Six known inotropes were tested: digoxin, dobutamine, isoprenaline

290 Inotropes were used in patients listed for transplant or

291 n, mechanical ventilation, vasopressors, and inotropes when appropriate.

292 operative ejection fraction and the need for inotropes when coming off bypass did not exhibit statist

293 f 200 advanced heart failure patients not on inotropes who met indications for LVAD implantation, com

294 Levosimendan is a new inotrope with calcium sensitization properties that impr

295 Thus, NO(-) is a redox-sensitive positive inotrope with selective venodilator action, whose cardia

296 insufficiency, and 40% were on at least two inotropes with a mean cardiac index of 1.8 L/min/m2.

297 Whether newer inotropes with differing mechanisms of action will reali

298 e pressure >/=24 mm Hg and dependent on >/=2 inotropes with or without intra-aortic balloon pump) wer

299 ntil transplantation; improvement leading to inotrope withdrawal; or death.

300 iogram (80%) and/or the need for intravenous inotropes within 7 days of hospital admission (69%).